8月5日,上海。2026沙利文峰会生命科学新投资高峰论坛上,一组数据让在场者屏息:2026年上半年,中国创新药对外授权(License-out)交易潜在总额达1100亿美元,交易规模达到2025年全年的八成。全球Top10 BD交易中,中国独占8席。 八年前,当港交所18A章刚刚落地时,中国创新药企还在用“烧十年钱、做研发、等审批”的循环艰难求生。如今,这个循环正在断裂——一条全新的资金入口正在...
Source Link8月5日,上海。2026沙利文峰会生命科学新投资高峰论坛上,一组数据让在场者屏息:2026年上半年,中国创新药对外授权(License-out)交易潜在总额达1100亿美元,交易规模达到2025年全年的八成。全球Top10 BD交易中,中国独占8席。 八年前,当港交所18A章刚刚落地时,中国创新药企还在用“烧十年钱、做研发、等审批”的循环艰难求生。如今,这个循环正在断裂——一条全新的资金入口正在...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.